129 related articles for article (PubMed ID: 9359487)
1. Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide prodrug in rats.
Chen BM; Chan LY; Wang SM; Wu MF; Chern JW; Roffler SR
Int J Cancer; 1997 Nov; 73(3):392-402. PubMed ID: 9359487
[TBL] [Abstract][Full Text] [Related]
2. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug.
Cheng TL; Wei SL; Chen BM; Chern JW; Wu MF; Liu PW; Roffler SR
Br J Cancer; 1999 Mar; 79(9-10):1378-85. PubMed ID: 10188879
[TBL] [Abstract][Full Text] [Related]
3. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs.
Cheng TL; Chen BM; Chan LY; Wu PY; Chern JW; Roffler SR
Cancer Immunol Immunother; 1997 Aug; 44(6):305-15. PubMed ID: 9298932
[TBL] [Abstract][Full Text] [Related]
4. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
5. Characterization of an antineoplastic glucuronide prodrug.
Cheng TL; Chou WC; Chen BM; Chern JW; Roffler SR
Biochem Pharmacol; 1999 Jul; 58(2):325-8. PubMed ID: 10423174
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy.
Chen BM; Cheng TL; Tzou SC; Roffler SR
Int J Cancer; 2001 Dec; 94(6):850-8. PubMed ID: 11745488
[TBL] [Abstract][Full Text] [Related]
7. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
[TBL] [Abstract][Full Text] [Related]
8. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy.
Cheng TL; Chen BM; Chern JW; Wu MF; Roffler SR
Bioconjug Chem; 2000; 11(2):258-66. PubMed ID: 10725103
[TBL] [Abstract][Full Text] [Related]
9. Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
Chuang KH; Cheng CM; Roffler SR; Lu YL; Lin SR; Wang JY; Tzou WS; Su YC; Chen BM; Cheng TL
Bioconjug Chem; 2006; 17(3):707-14. PubMed ID: 16704208
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate.
Wallace PM; Senter PD
Bioconjug Chem; 1991; 2(5):349-52. PubMed ID: 1790175
[TBL] [Abstract][Full Text] [Related]
11. Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.
Roffler SR; Wang SM; Chern JW; Yeh MY; Tung E
Biochem Pharmacol; 1991 Oct; 42(10):2062-5. PubMed ID: 1741786
[No Abstract] [Full Text] [Related]
12. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
13. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
15. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
16. Hapten-directed targeting to single-chain antibody receptors.
Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
[TBL] [Abstract][Full Text] [Related]
17. Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.
Cheng CM; Chen FM; Lu YL; Tzou SC; Wang JY; Kao CH; Liao KW; Cheng TC; Chuang CH; Chen BM; Roffler S; Cheng TL
Cancer Gene Ther; 2013 May; 20(5):276-81. PubMed ID: 23598434
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
[TBL] [Abstract][Full Text] [Related]
19. PET imaging of β-glucuronidase activity by an activity-based 124I-trapping probe for the personalized glucuronide prodrug targeted therapy.
Su YC; Cheng TC; Leu YL; Roffler SR; Wang JY; Chuang CH; Kao CH; Chen KC; Wang HE; Cheng TL
Mol Cancer Ther; 2014 Dec; 13(12):2852-63. PubMed ID: 25277385
[TBL] [Abstract][Full Text] [Related]
20. [Biodistribution of monoclonal antibody and Fab fragment and antitumor effect of their conjugates on hepatoma xenografts].
Li J; Zhen Y; Yang Z
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Oct; 16(5):328-33. PubMed ID: 7720121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
